Investors

Financial Calendar 2016
12 Oct - AGM
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Investor Contact
Bernard Ronchi
Senior Manager, Investor Relations
Phone: +613 9389 3470
bernard.ronchi@csl.com.au
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.

CSL Share Price

Visit our CSL Share Price page to access the quote table and price chart.

About CSL

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives.

With major facilities in Australia, Germany, Switzerland, United Kingdom and the U.S., CSL employs over 16,000 employees working in more than 30 countries.


ASX Releases

28/11/2016
Notice of Research & Development Investor Briefing
Investor R&D Briefing 2016 CSL Limited (ASX:CSL; USOTC:CSLLY) will be conducting its annual research & development briefing for investors on Thursday 1 December 2016 at 9.00am Australian Eastern Daylight Time (AEDT). It is anticipated the briefing will conclude at around 12 noon AEDT.
 
More.

16/11/2016
CSL Behring Presents Positive Results from CSL112 Phase 2b Trial
 CSL Limited (ASX:CSL; USOTC:CSLLY) - At the American Heart Association (AHA) Scientific Sessions in New Orleans, Louisiana, held on 15 November 2016, CSL Behring announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy.
 
More.

14/11/2016
AFSTYLA® (rFVIII-SC) - CHMP recommendation
Afstyla CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for CSL Behring’s AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.
 
More.

14/10/2016
New Debt Facilities
Maturity Profile of Debt by Facility 2016 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that on 13 October 2016 it closed a new USD550 million private placement in the US. The private placement was foreshadowed in CSL’s full year announcement in August 2016.
 
More.

30/08/2016
FDA Accepts CSL Behring’s BLA for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
FDA Accepts CSL Behring BLA CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has accepted for review CSL Behring’s Biologics License Application (BLA) for its low-volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy, CSL830, as prophylaxis to prevent Hereditary Angioedema (HAE) attacks.
 
More.

17/08/2016
Full Year Result 2016
CSL Delivers Another Strong Performance

FY Results 2016 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,242 million for the full year ended 30 June 2016.
 
More.

17/08/2016
CSL Announces Changes to the Board
Changes To The Board CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Dr Tadataka “Tachi” Yamada KBE has been appointed a Director effective from 1 September 2016. The Company also announced that Mr John Akehurst, has indicated his intention to retire from the CSL Board of Directors at the conclusion of the Company’s Annual General Meeting on 12 October 2016.
 
More.

26/05/2016
AFSTYLA® (rFVIII-Single Chain) – FDA approval
Afstyla CSL today announced that the US Food and Drug Administration (FDA) has approved AFSTYLA® [Antihaemophilic Factor (Recombinant), Single Chain], CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.
 
More.

24/05/2016
FLUCELVAX QUADRIVALENT™ (Influenza Vaccine) - FDA Approval
Holly Springs CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that the US Food and Drug Administration (FDA) has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged four years and older. FLUCELVAX QUADRIVALENT helps protect against the two influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
 
More.

12/05/2016
IDELVION® (rFIX-FP) - European Commission Approval
Idelvion CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that, following the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation to grant marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B in late February 2016, the European Commission has now approved IDELVION for the treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).
 
More.

14/03/2016
Seqirus Presentation to Investors/Analysts
Gordon Naylor, Russell Basser and Brent MacGregor deliver a presentation to investors and analysts during site tours at the Seqirus manufacturing facilities in Liverpool and Holly Springs. More.

07/03/2016
IDELVION® (rFIX-FP) – FDA approval
Idelvion CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B.
 
More.

29/02/2016
IDELVION® (rFIX-FP) - CHMP recommendation
Idelvion CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B.
 
More.

16/02/2016
CSL Appoints New Director
Megan Clark Announcement CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016.
 
More.

16/02/2016
Half Year Result 2016
CSL Delivers Exceptional Performance

Half Year Report 2016 CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1 NPAT grew 7% and EPS grew 9%, at constant currency2.
 
More.

Prior ASX Releases

>> View the ASX Archive


© 2016 CSL Limited